FDA Clears First Growing Artificial Heart Valve for Children, Cutting Repeated Surgeries

The U.S. Food and Drug Administration has granted clearance for a pediatric artificial heart valve that can enlarge as a child grows, a development expected to reduce the series of open‑heart operations traditionally required for certain congenital heart defects.

Congenital anomalies of the heart valves affect thousands of children each year, often necessitating valve replacement shortly after birth. Because existing prosthetic valves are fixed in size, surgeons must replace them repeatedly as the child's heart enlarges, exposing patients to cumulative surgical risk, prolonged hospital stays, and significant emotional and financial strain on families.

The newly approved device is engineered from a biocompatible material that can be expanded via minimally invasive catheter techniques, allowing the valve to accommodate the natural growth of the heart without the need for a full surgical replacement. Early clinical trials demonstrated that the valve maintained functional performance over several years while safely expanding in size, meeting the FDA’s criteria for safety and effectiveness.

Regulators reviewed data from multi‑center studies involving pediatric patients with conditions such as pulmonary valve stenosis and right‑ventricular outflow tract obstruction. The studies reported low rates of complications, stable hemodynamic measurements, and no need for re‑operation within the follow‑up period. Based on these findings, the agency issued a premarket approval, the most rigorous pathway for high‑risk medical devices.

Experts say the approval could transform the standard of care for young patients with valve disease. By limiting the number of open‑heart surgeries, the valve may lower long‑term healthcare costs, reduce exposure to anesthesia, and improve quality of life for children and their caregivers. Hospitals are already preparing to incorporate the technology into their pediatric cardiac programs.

Manufacturers plan to continue post‑market surveillance to track long‑term outcomes and to explore adaptations of the growth‑capable design for other cardiac applications. If the device performs as expected, it could pave the way for a new generation of implantable devices that adjust to a patient’s development, further reducing the procedural burden on vulnerable populations.